3. To perform a clinical study (stage 2 of the current study) of chemotherapy patients, and to identify subclinical LV dysfunction, which will be used to guide cardioprotective therapy using the new machine learning approach in comparison to the actual standard procedure using only echocardiographic left ventricular ejection fraction (LVEF).